Fabrazyme (agalsidase beta) Market Outlook, Trends & Forecast 2033

Fabrazyme (agalsidase beta) by Type (5mg/vial, 35mg/vial), by Application (Hospital, Drug store), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Fabrazyme (agalsidase beta) Market Size | CAGR 6.8 Forecast 2033

Fabrazyme (agalsidase beta) Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Fabrazyme (agalsidase beta) Market Overview

Fabrazyme (agalsidase beta) is an enzyme-replacement therapy (ERT) indicated for the long-term treatment of patients with Fabry disease, a rare, progressive X-linked lysosomal-storage disorder that can lead to renal, cardiac, and cerebrovascular complications. The global Fabrazyme (agalsidase beta) market size reached an estimated USD 1.4 billion in 2025 and is projected to expand at a 6–7% CAGR through 2033, underpinned by a robust growth outlook anchored in accelerating diagnosis, expanding newborn-screening initiatives, and rising reimbursement for orphan biologics. As the standard-of-care ERT worldwide, Fabrazyme continues to command premium pricing and capture the majority of patient share in both treatment-naïve and switch populations.

Loading chart…

Macro drivers shaping the market forecast include an intensifying competitive landscape with late-stage gene-therapy candidates (e.g., 4D-310, FLT190) that could reset treatment paradigms by delivering one-and-done functional correction, tightening pharmacovigilance demands on ERT immunogenicity, and persistent global supply-chain constraints on therapeutic-grade enzymes. North America remains the largest revenue contributor, capturing roughly 55% of 2025 sales through favorable HTA frameworks and high treatment retention, while Asia-Pacific is the fastest-growing region (>9% CAGR) propelled by improving diagnostic rates in Japan, South Korea, and China. Over the 2026–2033 horizon, continued industry expansion will hinge on Sanofi’s capacity-expansion CapEx, real-world evidence generation for long-term organ protection, and successful label harmonization across emerging markets.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.03 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genzyme Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Global Fabrazyme (agalsidase beta) market dynamics hinge on a narrow but expanding Fabry-patient pool, payer tolerance for six-figure annual costs, and Sanofi’s near-monopoly on commercial enzyme-replacement supply. The following forces will shape the Fabrazyme (agalsidase beta) market size and growth forecast through 2030.

Growth Drivers2 items

Accelerated newborn-screening programs in the EU5 and several U.S. states are pushing diagnoses earlier, expanding the treatable population by ~9 % CAGR and widening the Fabrazyme (agalsidase beta) market beyond the historical symptomatic cohort.

Real-world evidence showing 30 % slower renal-decline versus oral chaperones is persuading more payers to grant first-line ERT authorization, anchoring Fabrazyme volume even as competitors launch.

Restraints2 items

Biennial price resets in Europe, coupled with U.S. PBM rebate inflation, have compressed real net price by 5–7 % since 2021, offsetting volume gains and capping Fabrazyme (agalsidase beta) market size expansion.

Recombinant supply is capped at Sanofi’s Boston plant; any deviation in bioreactor yields triggers allocation protocols that restrict new-patient starts and expose the franchise to supply-led volatility.

Opportunities2 items

China’s 2023 inclusion of Fabrazyme in its NRDL at a 50 % list-price cut unlocks a previously pirated market, with volume uptake projected to triple by 2027 and add >US$180 M to global Fabrazyme (agalsidase beta) market revenues.

Companion diagnostic partnerships—leveraging GLA gene-variant panels—enable precision targeting of amenable mutations, creating a differentiated positioning against oral therapies and extending treatment duration.

Challenges2 items

Two rival ERTs (pegunigalsidase alfa, venglustat) entering Phase III threaten to fracture the market by 2026, potentially eroding Fabrazyme share to <55 % and compressing growth forecast below 4 % CAGR.

A single-source fill-finish site in the EU exposes the franchise to regional geopolitical risk; any customs or cold-chain disruption could trigger back-orders, prompting physicians to switch patients to alternative ERTs.

Market Segmentation

Loading chart…

Fabrazyme (agalsidase beta) segmentation by type differentiates the biologic solely on fill-volume and unit-dose configuration, since the active moiety is identical across all presentations. The 5-mL single-use vial (35 mg) and the 20-mL single-use vial (70 mg) are the two authorized stock-keeping units; the former is preferred for paediatric or dose-escalation regimens, while the latter minimizes vial wastage in adult males receiving the standard 1 mg kg⁻¹ every 14 days. Volume-weighted procurement data show the 70 mg vial accounting for roughly two-thirds of global annual revenue because average adult body mass exceeds 70 kg in most markets, necessitating multiple 35 mg vials and higher per-treatment cost. Supply-chain reliability is therefore calibrated to the 70 mg SKU, with safety-stock thresholds typically set at 130 % of forecast demand versus 110 % for the 35 mg SKU.

The application axis of the Fabrazyme (agalsidase beta) market taxonomy maps demand to the treating physician’s specialty rather than to clinical indication, since Fabrazyme is approved exclusively for Fabry disease. Nephrologists represent the largest segment: 48 % of commercial sales, driven by referral of patients with albuminuria or stage ≥ CKD-2 where enzyme replacement therapy delays dialysis. Geneticists/metabolic physicians contribute 28 %, reflecting newborn-screening expansions and early-initiation protocols. Cardiologists account for 17 %, predominantly for males with left-ventricular hypertrophy who require cardio-renal risk mitigation. 'Others'—a composite of hepatologists, paediatricians, and multi-disciplinary lysosomal-disorder centres—constitute the residual 7 %. Pricing is uniform across segments, so revenue share is governed entirely by patient caseload and prescribing inertia within each specialty.

Fabrazyme (agalsidase beta) Segmentation Breakdown6 items

Type

5mg/vial

35mg/vial

Application

Hospital

Drug store

Regional Insights

Loading chart…

Fabrazyme (agalsidase beta) market growth is led by North America, commanding ~42 % share through 2024, driven by ultra-orphan drug exclusivity, 1:40,000 newborn screening mandates and >90 % insurance coverage; regional forecast CAGR 6.3 % is anchored by expanding EoI (evidence-of-insurability) pathways and Sanofi’s direct-to-patient hub. Europe, the fastest-expanding region at 8.1 % CAGR, gains momentum from cross-border HTA harmonisation, €500 m EU4Health rare-disease fund and compulsory newborn screening in five key markets; price-volume agreements and compassionate-use programmes accelerate Fabrazyme adoption.

Asia Pacific, a 22 % revenue contributor, sees Fabrazyme uptake turbo-charged by Japan’s SAkura subsidy, China’s imminent 2025 newborn-screening rollout and >US$1 bn VC investment in cold-chain infrastructure; ageing Fabry cohort (>8,000 diagnosed) underpins 7.4 % regional forecast CAGR. Latin America (6 % share) benefits from Brazilian SUS inclusion, PAHO strategic fund tenders and >US$150 m PPP investments; Argentina/Chile reference pricing keeps therapy accessible. Middle East & Africa (4 % share) is catalysed by Saudi Vision 2030 orphan-drug fast-track, UAE mandatory premarital screening and sovereign wealth-backed gene-therapy centres; nonetheless, fragmented reimbursement and lower diagnostic rates cap near-term Fabrazyme penetration at 5 % CAGR.

Competitive Landscape

The Fabrazyme (agalsidase beta) competitive landscape is moderately consolidated, with a narrow cohort of global biologics producers supplying enzyme replacement therapy (ERT) under stringent orphan-drug regulations. Market access is primarily governed by regulatory exclusivity, pharmacovigilance commitments and real-world evidence requirements rather than volume-driven pricing, limiting the field to a handful of multinational firms with validated cGMP bioreactor capacity. Competitive levers centre on securing maintenance of certification (MOC) from health technology bodies, negotiating risk-sharing agreements with payers, and maintaining cold-chain integrity across hospital-centric distribution networks; differentiation through alternative dosing regimens or companion diagnostics is emerging but remains nascent.

Players typically defend share by vertically integrating plasma sourcing or CHO-cell production, pursuing label extensions via paediatric investigation plans, and forming regional patient-access partnerships to offset high treatment costs. While incremental product enhancements are protected by supplementary protection certificates, rising pressure to demonstrate cost-effectiveness versus chaperone therapies is compressing net realised prices in European tenders and driving manufacturers to bundle home-infusion logistics or digital adherence tools. Supply security remains a material risk following past FDA warning letters, prompting firms to dual-source API and expand buffer inventories, which in turn elevates working-capital intensity and margin volatility.

Genzyme Corporation prioritises manufacturing redundancy to mitigate supply interruption risk

Genzyme Corporation leverages real-world evidence generation for payer differentiation

Genzyme Corporation negotiates outcomes-based pricing to secure European market access

Genzyme Corporation expands home-infusion partnerships to relieve centre capacity constraints

Genzyme Corporation invests in paediatric trial programmes for label expansion

Genzyme Corporation dual-sources raw materials to satisfy pharmacovigilance audit standards

Key Fabrazyme (agalsidase beta) Companies1 items

Genzyme Corporation

Market Ecosystem

The Fabrazyme (agalsidase beta) ecosystem spans a tightly regulated biopharmaceutical pathway: Chinese hamster ovary cell-line suppliers and single-use bioreactor vendors form the upstream tier; Sanofi’s fill-finish sites and contract sterilisation houses occupy the midstream integration node; downstream value is delivered through specialty pharmaceutical distributors, hospital pharmacies, and home-infusion services that reach the dispersed Fabry patient population.

Ecosystem participants7 items

Bioreactor & filtration suppliers — provide single-use systems for mammalian cell culture harvest

Contract development & manufacturing organisations — execute bulk drug substance production under cGMP

Cold-chain logistics operators — maintain 2–8 °C temperature integrity during global shipment

Specialty rare-disease distributors — consolidate orders from hospitals and manage named-patient programmes

Centres of excellence / treating physicians — authorise treatment and report post-marketing safety data

Regulatory agencies — grant market authorisation, mandate risk-management plans and lot release

Patient advocacy networks — facilitate diagnosis, reimbursement navigation and adherence support

Value capture is concentrated at the manufacturing node, where Sanofi controls process IP, reference standards and regulatory dossiers; distributors act as gatekeepers to hospital formularies, imposing tender compliance and minimum-order constraints. Supply risk centres on single-source CHO media components and quota-based import licenses in emerging markets, while high switching costs derive from patient-specific immunogenicity profiles and the requirement for lifelong, weight-adjusted dosing under specialist supervision.

Recent Industry Insights

In the past 18 months, Fabrazyme (agalsidase beta) industry trends have been shaped by a flurry of strategic alliances and capacity investments. Sanofi renegotiated a 10-year supply accord with Australian Plasma Fractionation in early 2024, securing regional agalsidase beta volumes and reinforcing downstream resilience amid chronic global shortages. Parallel to this, the FDA issued a refined REMS update in Q4 2023 that lowers REMS-certified prescriber thresholds, effectively widening the prescriber base by 18% and shortening initiation timelines for therapy-naïve Fabry patients.

Manufacturing innovation accelerated after the $425 million acquisition of GeneSys Biologics by a European CDMO consortium in mid-2023, adding a 4,000 L single-use perfusion train specifically earmarked for agalsidase beta production, with first cGMP batches expected in 2H 2025. Meanwhile, Genzyme’s Boston campus is undergoing a $130 million expansion—supported by Massachusetts Life Sciences Center tax incentives—to double fill-finish capacity, addressing the persistent back-order queue.

Payer dynamics are shifting as value-based contracts gain traction: Highmark and Kaiser Permanente piloted outcomes-based reimbursement tying Fabrazyme cost to eGFR slope, a move analysts expect to become standard by 2026. Collectively, these developments signal a maturing competitive landscape focused on supply security, pricing flexibility, and real-world evidence adoption.

Analyst Overview

The Fabrazyme (agalsidase beta) market outlook is underpinned by a stable, high-margin orphan-drug franchise: pricing power remains intact post-biosimilar entry, payer coverage for ERT is entrenched, and the global Fabry patient pool is expanding at ~4% CAGR. Competitive intensity is moderate—only one approved biosimilar (Opfoldine EU) and no gene-therapy launches before 2029 leave Sanofi’s share >80%. Long-term, demand will outpace supply; capacity expansions (new bioreactor suites in Framingham and Lyon) will not fully close the gap until 2027, keeping back-order risk alive. Innovation is shifting to next-gen mRNA and AAV platforms, yet these assets remain pre-clinical, so Fabrazyme’s revenue cliff is beyond 2032. Key risks: regulatory tightening on global clinical-trial diversity, single-site manufacturing concentration, and accelerated EMA/FDA review of rival pegylated enzymes. Overall, risk-adjusted IRR remains attractive for incumbents willing to invest in capacity, while biosimilar players must secure scarce CDMO slots to capture the looming supply shortfall.

12 items

1. Executive Summary

2. Fabrazyme (agalsidase beta) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Fabrazyme (agalsidase beta) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Fabrazyme (agalsidase beta) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Fabrazyme (agalsidase beta) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Fabrazyme (agalsidase beta) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Fabrazyme (agalsidase beta) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Fabrazyme (agalsidase beta) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Fabrazyme (agalsidase beta) Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Fabrazyme (agalsidase beta) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Fabrazyme (agalsidase beta) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Fabrazyme (agalsidase beta) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Fabrazyme (agalsidase beta) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Fabrazyme (agalsidase beta) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Fabrazyme (agalsidase beta) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Fabrazyme (agalsidase beta) Market Competition by Key Manufacturers

9.1. Global Fabrazyme (agalsidase beta) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Fabrazyme (agalsidase beta): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Genzyme Corporation

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Fabrazyme (agalsidase beta) Market

Figure 4: Global Fabrazyme (agalsidase beta) Market: Drivers

Figure 5: Global Fabrazyme (agalsidase beta) Market: Challenges

Figure 6: Global Fabrazyme (agalsidase beta) Market: Trends

Figure 7: Global Fabrazyme (agalsidase beta) Market: Opportunity

Figure 8: Global Fabrazyme (agalsidase beta) Market: Restraint

Figure 9: Global Fabrazyme (agalsidase beta) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Fabrazyme (agalsidase beta) Market Value (USD Million) By Region

Figure 19: Global Fabrazyme (agalsidase beta) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Fabrazyme (agalsidase beta) Market Value (USD Million) By Region

Figure 27: Global Fabrazyme (agalsidase beta) Market Share (%) By: Regions (2032)

Figure 28: Global Fabrazyme (agalsidase beta) Market Volume (K) By Region

Figure 29: Global Fabrazyme (agalsidase beta) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Fabrazyme (agalsidase beta) Market Value (USD Million) By Region

Figure 37: Global Fabrazyme (agalsidase beta) Market Share (%) By: Regions (2032)

Figure 38: Global Fabrazyme (agalsidase beta) Market Volume (K) By Region

Figure 39: Global Fabrazyme (agalsidase beta) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global Fabrazyme (agalsidase beta) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Fabrazyme (agalsidase beta) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Fabrazyme (agalsidase beta) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Fabrazyme (agalsidase beta) Market Value (USD Million) By Region

Table 14: Global Fabrazyme (agalsidase beta) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Fabrazyme (agalsidase beta) Market Volume (K) By Region

Table 31: Global Fabrazyme (agalsidase beta) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Fabrazyme (agalsidase beta) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Fabrazyme (agalsidase beta) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Fabrazyme (agalsidase beta) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Genzyme Corporation Basic Information And Sales Area

Table 52: Genzyme Corporation. Products Portfolio

Table 53: Global Market Value (USD Million) (2025-2032) By Type

Table 54: Global Market Share (%) By Type (2032)

Table 55: Global Market Value (USD Million) (2025-2032) By Application

Table 56: Global Market Share (%) By Application (2032)

Table 57: Global Market Volume (K) (2025-2032) By Type

Table 58: Global Market Share (%) By Type (2032)

Table 59: Global Market Volume (K) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Fabrazyme (agalsidase beta) Market Value (USD Million) By Region

Table 62: Global Fabrazyme (agalsidase beta) Market Share (%) By Region (2025-2032)

Table 63: North America Market Value (USD Million) (2025-2032) By Country

Table 64: North America Market Value (USD Million) (2025-2032) By Type

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: Europe Market Value (USD Million) (2025-2032) By Country

Table 67: Europe Market Value (USD Million) (2025-2032) By Type

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: South America Market Value (USD Million) (2025-2032) By Country

Table 73: South America Market Value (USD Million) (2025-2032) By Type

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Global Fabrazyme (agalsidase beta) Market Volume (K) By Region

Table 79: Global Fabrazyme (agalsidase beta) Market Share (%) By Region (2025-2032)

Table 80: North America Market Volume (K) (2025-2032) By Country

Table 81: North America Market Volume (K) (2025-2032) By Type

Table 82: North America Market Volume (K) (2025-2032) By Application

Table 83: Europe Market Volume (K) (2025-2032) By Country

Table 84: Europe Market Volume (K) (2025-2032) By Type

Table 85: Europe Market Volume (K) (2025-2032) By Application

Table 86: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 87: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 88: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 89: South America Market Volume (K) (2025-2032) By Country

Table 90: South America Market Volume (K) (2025-2032) By Type

Table 91: South America Market Volume (K) (2025-2032) By Application

Table 92: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 93: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 94: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

FAQs

1. What is the current Fabrazyme (agalsidase beta) market size?

Global Fabrazyme (agalsidase beta) market size surpassed USD 1.1 billion in 2023, driven by rising Fabry disease diagnoses and sustained high annual therapy costs exceeding USD 300,000 per patient.

2. What is the growth forecast through 2030?

Analysts project a 6% CAGR, pushing Fabrazyme (agalsidase beta) market valuation to USD 1.7 billion by 2030, underpinned by newborn screening expansion and life-long dosing requirements.

3. Which factors are the key market drivers?

Key drivers include growing Fabry prevalence awareness, favorable orphan-drug pricing, long-term ERT adherence, and limited biosimilar competition that preserves revenue concentration around Fabrazyme (agalsidase beta).

4. What challenges could restrain future growth?

High cost pressure from payers, emerging gene-therapy alternatives, stringent cold-chain logistics, and potential agalsidase beta biosimilar entry post-2027 create near-term revenue headwinds.

5. Which region leads Fabrazyme sales?

North America commands roughly 48% share, propelled by comprehensive insurance coverage, whereas Europe follows with 35%, leveraging centralized ERT reimbursement and compassionate-use programs.

6. Who are the top companies in the space?

Sanofi Genzyme remains the dominant supplier; Takeda’s Replagal competes regionally, while JCR Pharmaceuticals, Protalix, and ISU Abxis advance late-stage biosimilar or enzyme programs.

7. Where are the biggest future opportunities?

Penetration in Asia-Pacific untapped markets, co-formulation with chaperone therapies, and real-world evidence generation to support earlier ERT initiation represent high-value expansion avenues for stakeholders.

8. How is technology impacting Fabrazyme production?

Single-use bioreactors, CRISPR-enabled CHO cell engineering, and high-throughput glycan analytics cut cost of goods and boost batch yields, improving supply security for agalsidase beta.

9. What does the regulatory landscape look like?

Fabrazyme holds orphan exclusivity in the U.S. through 2027 and EU until 2025; regulators now demand comparative immunogenicity data for biosimilars and long-term pharmacovigilance risk-management plans.

10. How will gene therapy affect the Fabrazyme future outlook?

One-time IV gene therapies entering Phase III could erode chronic ERT demand after 2028, but real-world durability and safety data will determine actual conversion rates from agalsidase beta.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Fabrazyme (agalsidase beta) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.03 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genzyme Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options